ProShares Trust (BIB)
Management Company · XNAS · Series S000018718 · View on SEC EDGAR ↗
$126.22
As of Aug. 19, 2026
▲ +14.24 (+12.71%)
1-day change
$54.56 – $126.40
52-week range
- Net assets
- $73.7M
- Holdings
- 267
- As of
- May 31, 2026
- Top 10 holdings weight
- 42.99%
- Effective number of positions
- 40.3
- Positions above 1%
- 20
On this page
- Price chart The fund's market price over time, with technical overlays.
- Performance Total return, volatility, drawdown and other risk metrics.
- Fund flows Money flowing in and out of the fund each month, from N-PORT filings.
- Holdings Every position the fund currently holds, with weights.
- Sector breakdown How the fund's holdings split across market sectors.
- Institutional owners 13F institutions that report holding this ETF.
- Similar funds Other funds with overlapping holdings or comparable size.
BIB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
Performance as of March 10, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▲ +1.07% | — |
| 3M | ▲ +7.05% | — |
| 6M | ▲ +49.02% | — |
| YTD | ▲ +6.58% | — |
| 1Y | ▲ +57.26% | — |
| 3Y | — | — |
| 5Y | — | — |
| Max since Feb. 27, 2024 | ▲ +36.57% | — |
- Volatility 1Y
- 45.98%
- Volatility 3Y
- —
- Max drawdown 3Y
- —
- Beta 3Y
- —
- Sharpe 1Y*
- 1.23
Total return is shown once dividend history for this fund has been collected — price return alone would duplicate it misleadingly. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
- Last month (May 2026)
- -$4.8M
- Quarter ending May 2026
- -$13.9M
- Trailing 12 months
- -$12.0M
Jun 2025 – May 2026
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 267 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | 766559702 | $20K | 0.03 | 672 | EC | US |
| Aclaris Therapeutics, Inc. | 00461U105 | $20K | 0.03 | 4,459 | EC | US |
| Prothena Corp. plc | — | $20K | 0.03 | 1,989 | EC | IE |
| 4D Molecular Therapeutics, Inc. | 35104E100 | $19K | 0.03 | 1,885 | EC | US |
| Aquestive Therapeutics, Inc. | 03843E104 | $18K | 0.02 | 4,511 | EC | US |
| Allogene Therapeutics, Inc. | 019770106 | $18K | 0.02 | 8,308 | EC | US |
| Kyverna Therapeutics, Inc. | 501976104 | $18K | 0.02 | 2,112 | EC | US |
| Aura Biosciences, Inc. | 05153U107 | $18K | 0.02 | 2,349 | EC | US |
| Fulcrum Therapeutics, Inc. | 359616109 | $17K | 0.02 | 2,464 | EC | US |
| Upstream Bio, Inc. | 91678A107 | $17K | 0.02 | 1,997 | EC | US |
| Kamada Ltd. | — | $17K | 0.02 | 2,134 | EC | IL |
| Pacific Biosciences of California, Inc. | 69404D108 | $17K | 0.02 | 11,163 | EC | US |
| First Tracks Biotherapeutics, Inc. | 337185102 | $16K | 0.02 | 1,023 | EC | US |
| Neurogene, Inc. | 64135M105 | $16K | 0.02 | 571 | EC | US |
| C4 Therapeutics, Inc. | 12529R107 | $16K | 0.02 | 3,609 | EC | US |
| Evolus, Inc. | 30052C107 | $16K | 0.02 | 2,397 | EC | US |
| Lakefront Biotherapeutics NV | 36315X101 | $16K | 0.02 | 548 | EC | BE |
| Contineum Therapeutics, Inc. | 21217B100 | $15K | 0.02 | 1,124 | EC | US |
| OmniAb, Inc. | 68218J103 | $14K | 0.02 | 5,322 | EC | US |
| Altimmune, Inc. | 02155H200 | $14K | 0.02 | 4,631 | EC | US |
| Enanta Pharmaceuticals, Inc. | 29251M106 | $14K | 0.02 | 1,072 | EC | US |
| Vanda Pharmaceuticals, Inc. | 921659108 | $14K | 0.02 | 2,186 | EC | US |
| Larimar Therapeutics, Inc. | 517125100 | $14K | 0.02 | 4,014 | EC | US |
| Autolus Therapeutics plc | 05280R100 | $14K | 0.02 | 7,414 | EC | GB |
| Lexeo Therapeutics, Inc. | 52886X107 | $14K | 0.02 | 2,697 | EC | US |
| Immuneering Corp. | 45254E107 | $14K | 0.02 | 2,387 | EC | US |
| Lyell Immunopharma, Inc. | 55083R203 | $14K | 0.02 | 787 | EC | US |
| Atea Pharmaceuticals, Inc. | 04683R106 | $13K | 0.02 | 2,889 | EC | US |
| Puma Biotechnology, Inc. | 74587V107 | $13K | 0.02 | 1,879 | EC | US |
| Cabaletta Bio, Inc. | 12674W109 | $13K | 0.02 | 3,557 | EC | US |
| REGENXBIO, Inc. | 75901B107 | $13K | 0.02 | 1,873 | EC | US |
| Keros Therapeutics, Inc. | 492327101 | $13K | 0.02 | 1,125 | EC | US |
| Editas Medicine, Inc. | 28106W103 | $12K | 0.02 | 3,611 | EC | US |
| SIGA Technologies, Inc. | 826917106 | $12K | 0.02 | 2,646 | EC | US |
| Rocket Pharmaceuticals, Inc. | 77313F106 | $12K | 0.02 | 4,013 | EC | US |
| Silence Therapeutics plc | 82686Q101 | $12K | 0.02 | 1,736 | EC | GB |
| Invivyd, Inc. | 00534A102 | $12K | 0.02 | 10,244 | EC | US |
| Neumora Therapeutics, Inc. | 640979100 | $11K | 0.02 | 6,176 | EC | US |
| Alpha Teknova, Inc. | 02080L102 | $11K | 0.01 | 1,981 | EC | US |
| Anavex Life Sciences Corp. | 032797300 | $10K | 0.01 | 3,426 | EC | US |
| Entrada Therapeutics, Inc. | 29384C108 | $10K | 0.01 | 1,416 | EC | US |
| AC Immune SA | — | $10K | 0.01 | 3,721 | EC | CH |
| Humacyte, Inc. | 44486Q103 | $9K | 0.01 | 7,136 | EC | US |
| Foghorn Therapeutics, Inc. | 344174107 | $9K | 0.01 | 2,165 | EC | US |
| Codexis, Inc. | 192005106 | $9K | 0.01 | 3,341 | EC | US |
| LENZ Therapeutics, Inc. | 52635N103 | $9K | 0.01 | 1,158 | EC | US |
| Coherus Oncology, Inc. | 19249H103 | $9K | 0.01 | 5,525 | EC | US |
| Quantum-Si, Inc. | 74765K105 | $9K | 0.01 | 7,230 | EC | US |
| Voyager Therapeutics, Inc. | 92915B106 | $8K | 0.01 | 2,179 | EC | US |
| Sagimet Biosciences, Inc. | 786700104 | $8K | 0.01 | 1,147 | EC | US |
Page 5
of 6
Sector breakdown
Healthcare
64.1%
Other/Unmapped
35.9%
Institutional owners (13F) 22 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785,973 | 21.94% | 7,802 | Shares | June 30, 2026 |
| Capital Investment Advisors, LLC | $599,013 | 16.72% | 5,946 | Shares | June 30, 2026 |
| Kaizen Financial Strategies | $535,554 | 14.95% | 5,315 | Shares | June 30, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413,034 | 11.53% | 4,100 | Call option | June 30, 2026 |
| Palumbo Wealth Management LLC | $402,960 | 11.25% | 4,000 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $302,220 | 8.44% | 3,000 | Call option | June 30, 2026 |
| Jump Financial, LLC | $257,189 | 7.18% | 2,553 | Shares | June 30, 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102,957 | 2.87% | 1,022 | Shares | June 30, 2026 |
| FRANKLIN RESOURCES INC | $70,115 | 1.96% | 696 | Shares | June 30, 2026 |
| PNC Financial Services Group, Inc. | $50,370 | 1.41% | 500 | Shares | June 30, 2026 |
| Ashton Thomas Private Wealth, LLC | $37,576 | 1.05% | 373 | Shares | June 30, 2026 |
| Truvestments Capital LLC | $12,593 | 0.35% | 125 | Shares | June 30, 2026 |
| Axiom Investment Management LLC | $5,037 | 0.14% | 50 | Shares | June 30, 2026 |
| Qube Research & Technologies Ltd | $4,936 | 0.14% | 49 | Shares | June 30, 2026 |
| SIMPLEX TRADING, LLC | $1,309 | 0.04% | 13 | Shares | June 30, 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0.01% | 2,400 | Shares | June 30, 2026 |
| Rockefeller Capital Management L.P. | $201 | 0.01% | 2 | Shares | June 30, 2026 |
| MORGAN STANLEY | $131 | 0.00% | 1 | Shares | June 30, 2026 |
| UBS Group AG | $101 | 0.00% | 1 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0.00% | 1 | Shares | June 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0.00% | 198 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $0 | 0.00% | 1 | Shares | June 30, 2026 |
Peer funds
More from this issuer
Similar by size
| Fund | AUM |
|---|---|
| AMUU Direxion Shares ETF Trust | $74.2M |
| DTEC ALPS ETF Trust | $74.4M |
| ENZL iShares Trust | $74.5M |
| DIG ProShares Trust | $74.6M |
| XOCT First Trust Exchange-Traded Fun… | $74.9M |
| ITDE iShares Trust | $73.3M |
| EIRL iShares Trust | $72.8M |
| FDIV EA Series Trust | $72.7M |
| DBEZ DBX ETF Trust | $72.7M |
| ITDB iShares Trust | $72.6M |